CMXC - Cell MedX Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.16
0.00 (0.00%)
As of 2:51PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.16
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume3,159
Market Cap7.085M
Beta-1.14
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Newsfile9 months ago

    Cell MedX Corp. Provides Corporate Update

    Carson City, Nevada--(Newsfile Corp. - August 31, 2017) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is excited to provide its shareholders with the corporate update on its current operations. Private PlacementThe Company's board of directors has approved a private placement offering of up to 8,000,000 units of the ...

  • Newsfile10 months ago

    Cell MedX Corp. Provides Update on its Clinical Observational Trial

    Carson City, Nevada--(Newsfile Corp. - July 31, 2017) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is excited to announce that all 30 subjects taking part in the Company's ongoing clinical observational trial carried out by Dr. Tytus and his team at Hamilton Medical Research Group (the "Trial") have ...

  • Newsfile11 months ago

    Cell MedX Corp. Provides Corporate Update

    Carson City, Nevada--(Newsfile Corp. - July 5, 2017) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is excited to announce that its currently ongoing clinical observational trial carried out by Dr. Tytus and his team at Hamilton Medical Research Group (the "Trial") is nearing its completion. To date, 29 ...